Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Sponsor: Beijing 302 Hospital
Summary
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.
Official title: The Safety and Efficacy of Sequential Combination Therapy With PD-1 Antibody and Pegylated Interferon-α in NA-supressed Chronic Hepatitis B Patients
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-06-15
Completion Date
2025-12-15
Last Updated
2024-06-20
Healthy Volunteers
No
Conditions
Interventions
Sintilimab
100mg/10ml/1bottle
NAs
tablets
Peg-IFNα-2b
180ug/0.5ml/1bottle
Locations (1)
the Fifth Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China